431 related articles for article (PubMed ID: 11248608)
1. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
Zinner NR; Mattiasson A; Stanton SL
J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Homma Y; Paick JS; Lee JG; Kawabe K;
BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
5. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
Swift S; Garely A; Dimpfl T; Payne C;
Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
[TBL] [Abstract][Full Text] [Related]
7. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
[TBL] [Abstract][Full Text] [Related]
9. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
Abrams P; Freeman R; Anderström C; Mattiasson A
Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
[TBL] [Abstract][Full Text] [Related]
10. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
Malone-Lee JG; Walsh JB; Maugourd MF
J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
[TBL] [Abstract][Full Text] [Related]
13. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.
Freeman R; Hill S; Millard R; Slack M; Sutherst J;
Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951
[TBL] [Abstract][Full Text] [Related]
14. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
Appell RA; Abrams P; Drutz HP; Van Kerrebroeck PE; Millard R; Wein A
World J Urol; 2001 Apr; 19(2):141-7. PubMed ID: 11374317
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder.
Kreder K; Mayne C; Jonas U
Eur Urol; 2002 Jun; 41(6):588-95. PubMed ID: 12074774
[TBL] [Abstract][Full Text] [Related]
16. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
Jacquetin B; Wyndaele J
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
Takei M; Homma Y;
Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
[TBL] [Abstract][Full Text] [Related]
19. Tolterodine: a review of its use in the treatment of overactive bladder.
Clemett D; Jarvis B
Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
[TBL] [Abstract][Full Text] [Related]
20. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
Rovner ES; Wein AJ
Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
